An agonist of human complement fragment C5a enhances vaccine immunity against Coccidioides infection

Vaccine

Volumn 30, Issue 31, 2012, Pages 4681-4690

  Hung, Chiung Yu ^a   Hurtgen, Brady J ^a,d   Bellecourt, Michael ^a   Sanderson, Sam D ^b   Morgan, Edward L ^c   Cole, Garry T ^a  

^a UNIVERSITY OF TEXAS AT SAN ANTONIO   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c SAN DIEGO STATE UNIVERSITY   (United States)

^d UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Adjuvant; C5a; Coccidioides; EP67; Vaccine

Indexed keywords

COMPLEMENT COMPONENT C5A; EP 67; GAMMA INTERFERON; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 17; LIVE VACCINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN PRESENTING CELL; ARTICLE; BAGG ALBINO MOUSE; CARBOXY TERMINAL SEQUENCE; CD4+ T LYMPHOCYTE; CELL ASSAY; CELL DIFFERENTIATION; COCCIDIOIDOMYCOSIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; DRUG CONJUGATION; DRUG EFFICACY; DRUG RECALL; FEMALE; FUNGUS SPORE; IMMUNIZATION; IN VITRO STUDY; LUNG INFILTRATE; MACROPHAGE; MOUSE; NEUTROPHIL COUNT; NONHUMAN; NUCLEOTIDE SEQUENCE; PATHOGEN LOAD; PRIORITY JOURNAL; SPLEEN CELL; SURVIVAL; TH1 CELL; TH17 CELL;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, FUNGAL; ANTIGEN-PRESENTING CELLS; COCCIDIOIDES; COCCIDIOIDOMYCOSIS; COMPLEMENT C5A; FEMALE; FUNGAL VACCINES; HUMANS; IMMUNITY, CELLULAR; INTERFERON-GAMMA; INTERLEUKIN-17; MICE; MICE, INBRED BALB C; PEPTIDES; TH1 CELLS; TH17 CELLS; VACCINES, ATTENUATED;

EID: 84861991335     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.04.084     Document Type: Article

References (50)

1. Galgiani J.N., Ampel N.M., Blair J.E., Catanzaro A., Johnson R.H., Stevens D.A., et al. Coccidioidomycosis. Clinical Infectious Diseases 2005, 41:1217-1223.
2. Sharpton T.J., Stajich J.E., Rounsley S.D., Gardner M.J., Wortman J.R., Jordar V.S., et al. Comparative genomic analyses of the human fungal pathogens Coccidioides and their relatives. Genome Research 2009, 19:1722-1731.
3. Hector R.F., Rutherford G.W., Tsang C.A., Erhart L.M., McCotter O., et al. The public health impact of coccidioidomycosis in Arizona and California. International Journal of Environmental Research and Public Health 2011, 8:1150-1173.
4. Cole G.T., Xue J.M., Okeke C.N., Tarcha E.J., Basrur V., Schaller R.A., et al. A vaccine against coccidioidomycosis is justified and attainable. Medical Mycology 2004, 42:189-216.
5. Tsang C.A., Anderson S.M., Imholte S.B., Erhart L.M., Chen S., Park B.J., et al. Enhanced surveillance of coccidioidomycosis, Arizona, USA, 2007-2008. Emerging Infectious Diseases 2010, 16:1738-1744.
6. Pappagianis D. Seeking a vaccine against Coccidioides immitis and serologic studies: expectations and realities. Fungal Genetics and Biology 2001, 32:1-9.
7. Wüthrich M., Gern B., Hung C.-Y., Ersland K., Rocco N., Pick-Jacobs J., et al. Vaccine-induced protection against 3 systemic mycoses endemic to North America requires Th17 cells in mice. Journal of Clinical Investigation 2011, 121:554-568.
8. Hung C.Y., Gonzalez A., Wüthrich M., Klein B.S., Cole G.T. Vaccine immunity to coccidioidomycosis occurs by early activation of three signal pathways of T helper cell response (Th1, Th2 and Th17). Infection and Immunity 2011, 79:4511-4522.
9. Sorensen K.N., Clemons K.V., Stevens D.A. Murine models of blastomycosis, coccidioidomycosis, and histoplasmosis. Mycopathologia 1999, 146:53-65.
10. Kirkland T.N., Fierer J. Inbred mouse strains differ in resistance to lethal Coccidioides immitis infection. Infection and Immunity 1983, 40:912-916.
11. Xue J., Chen X., Selby D., Hung C.Y., Yu J.J., Cole G.T. A genetically engineered live attenuated vaccine of Coccidioides posadasii protects BALB/c mice against coccidioidomycosis. Infection and Immunity 2009, 77:3196-3208.
12. Morgan E.L., Morgan B.N., Stein E.A., Vitrs E.L., Thoman M.L., Sanderson S.D., et al. Enhancement of in vivo and in vitro immune functions by a conformationally biased, response-selective agonist of human C5a: implications for a novel adjuvant in vaccine design. Vaccine 2009, 28:463-469.
13. Morgan E.L., Thoman M.L., Sanderson S.D., Phillips J.A. A novel adjuvant for vaccine development in the aged. Vaccine 2010, 28:8275-8279.
14. Taylor S.M., Sherman S.A., Kirnarsky L., Sanderson S.D. Development of response-selective agonists of human C5a anaphylatoxin: conformational, biological, and therapeutic considerations. Current Medicinal Chemistry 2001, 8:675-684.
15. Vogen S.M., Paczkowski N.J., Kirnarsky L., Short A., Whitmore J.B., Sherman S.A., et al. Differential activities of decapeptide agonists of human C5a: the conformational effects of backbone N-methylation. International Immunopharmacology 2001, 1:2151-2162.
16. Hegde G.V., Meyers-Clark E., Joshi S.S., Sanderson S.D. A conformationally-biased, response-selective agonist of C5a acts as a molecular adjuvant by modulating antigen processing and presentation activities of human dendritic cells. International Immunopharmacology 2008, 8:819-827.
17. Duryee M.J., Bevins R.A., Reichel C.M., Murray J.E., Dong Y., Thiele G.M., et al. Immune responses to methamphetamine by active immunization with peptide-based, molecular adjuvant-containing vaccines. Vaccine 2009, 27:2981-2988.
18. Sanderson S.D., Cheruku S.R., Padmanilayam M.P., Vennerstrom J.L., Thiele G.M., Palmatier M.I., et al. Immunization to nicotine with a peptide-based vaccine composed of a conformationally biased agonist of C5a as a molecular adjuvant. International Immunopharmacology 2003, 3:137-146.
19. Phillips J.A., Morgan E.L., Dong Y., Cole G.T., McMahan C., Hung C.-Y., et al. Single-step conjugation of bioactive peptides to proteins via a self-contained succinimidyl bis-arylhydrazone. Bioconjugate Chemistry 2009, 20:1950-1957.
20. Gonzalez A., Hung C-Y., Cole G.T. Nitric oxide synthase activity has limited influence on the control of Coccidioides infection in mice. Microbial Pathogenesis 2011, 51:161-168.
21. Ampel N.M., Kramer L.A., Li L., Carroll D.S., Kerekes K.M., Johnson S.M., et al. In vitro whole-blood analysis of cellular immunity in patients with active coccidioidomycosis by using the antigen preparation T27K. Clinical and Diagnostic Laboratory Immunology 2002, 9:1039-1043.
22. Szabo S.J., Kim S.T., Costa G.L., Zhang X.C., Fathman C.G., Glimcher L.H. A novel transcription factor, T-bet, directs Th1 lineage commitment. Cell 2000, 100:655-669.
23. Zhang D.H., Cohn L., Ray P., Bottomly K., Ray A. Transcription factor Gata-3 is differentially expressed in murine Th1 and Th2 cells and controls Th2-specific expression of the Interleukin-5 gene. Journal of Biological Chemistry 1997, 272:21597-21603.
24. Yang X.O., Pappu B.P., Nurieva R., Akimzhanov A., Kang H.S., Chung Y., et al. T helper 17 lineage differentiation is programmed by orphan nuclear receptors RORα and RORγ. Immunity 2008, 28:29-39.
25. + regulatory T cells: differentiation, specification, subphenotypes. Nature Immunology 2009, 10:689-695.
26. Xue J., Hung C-Y., Yu J-J., Cole G.T. Immune response of vaccinated and non-vaccinated mice to Coccidioides posadasii infection. Vaccine 2005, 23:3535-3544.
27. Hardison S.E., Wozniak K.L., Kolls J.K., Wormley F.L. Interleukin-17 is not required for classical macrophage activation in a pulmonary mouse model of Cryptococcus neoformans infection. Infection and Immunity 2011, 78:5341-5351.
28. Li K., Yu J-J., Hung C-Y., Lehmann P.F., Cole G.T. Recombinant urease and urease DNA of Coccidioides immitis elicit an immunoprotective response against coccidioidomycosis in mice. Infection and Immunity 2001, 69:2878-2887.
29. Hung C.-Y., Seshan K.R., Yu J.-J., Schaller R., Xue J., Basrur V., et al. A metalloproteinase of Coccidioides posadasii contributes to evasion of host detection. Infection and Immunity 2005, 73:6689-6703.
30. Coffman R.L., Sher A., Seder R.A. Vaccine adjuvants: putting innate immunity to work. Immunity 2010, 33:492-503.
31. Baumgartner C.K., Malherbe L.P. Antigen-driven T-cell repertoire selection during adaptive immune responses. Immunology and Cell Biology 2011, 89:54-59.
32. Lin L., Ibrahim A.S., Xu X., Farber J.M., Avanesian V., Baquir B., et al. Th1-Th17 cells mediate protective adaptive immunity against Staphylococcus aureus and Candida albicans infection in mice. PLoS Pathogens 2009, 5:e1000703.
33. Zimmermann C.R., Johnson S.M., Martens G.W., White A.G., Zimmer B.L., Pappagianis D. Protection against lethal murine coccidioidomycosis by a soluble vaccine from spherules. Infection and Immunity 1998, 66:2342-2345.
34. Kirkland T.N., Cole G.T. Coccidioidomycosis pathogenesis, immune response and vaccine development. Fungal pathogenesis: principles and applications 2002, 365-399. Marcel Dekker, New York. R.A. Calderone, L.C. Cihlar (Eds.).
35. Singh M., Srivastava I. Advances in vaccine adjuvants for infectious diseases. Current HIV Research 2003, 1:309-320.
36. Abuodeh R.O., Shubitz L.F., Siegel E., Snyder S., Peng T., Orsborn K.I., et al. Resistance to Coccidioides immitis in mice after immunization with recombinant protein or a DNA vaccine of a proline-rich antigen. Infection and Immunity 1999, 67:2935-2940.
37. Liu B., Zhang L., Liu J., Shan F., Wang E., Kimura Y A prophylactic effect of an oligodeoxynucleotide containing a cytidine-guanosine motif against Japanese cedar pollen-induced T-helper type 2 allergic response. Journal of Asthma 2011, 48:973-978.
38. Cox R.A., Magee D.M. Coccidioidomycosis host response and vaccine development. Clinical Microbiology Reviews 2004, 17:804-839.
39. Werner J.L., Gessner M.A., Lilly L.M., Nelson M.P., Metz A.E., Horn D., et al. Neutrophils produce interleukin 17a (IL-17a) in a dectin-1- and IL-23-dependent manner during invasive fungal infection. Infection and Immunity 2011, 79:3966-3977.
40. Macagno A., Neopolitani G., Lanzavecchia A., Sallusto F. Duration, combination and timing: the signal integration model of dendritic cell activation. Trends in Immunology 2007, 28:227-233.
41. Huang H., Ostroff G.R., Lee C.K., Specht C.A., Levitz S.M. Robust stimulation of humoral and cellular immune responses following vaccination with antigen-loaded β-glucan particles. mBio 2010, 1. e00164-10.
42. Peng Q., Li K., Wang N., Li Q., Asgari E., Lu B., et al. Dendritic cell function in allostimulation is modulated by C5aR signaling. Journal of Immunology 2009, 183:6058-6068.
43. Vilekar P., Awasthi V., Lagisetty P., King C., Shankar N., Awasthi S. In vivo trafficking and immunostimulatory potential of an intranasally-administered primary dendritic cell-based vaccine. BMC Immunology 2010, 11:60-77.
44. Wang L., Lin J., Zhou Z., Huo R., Shen B., Li N. Up-regulation of Th 17 cells may underlie inhibition of Treg development caused by immunization with activated syngeneic T cells. PLoS ONE 2011, 6:e27289.
45. Barton B.E. IL-6: insights into novel biological activities. Clinical Immunology and Immunopathology 1997, 85:16-20.
46. Onishi R.M., Gaffen S.L. Interleukin-17 and its target genes: mechanisms of interleukin-17 function in disease. Immunology 2010, 129:311-321.
47. Lexberg M.H., Taubner A., Albrecht I., Lepenies I., Richter A., Kamradt T., et al. IFN-γ and IL-12 synergize to convert in vivo generated Th17 into Th1/Th17 cells. European Journal of Immunology 2010, 40:3017-3027.
48. Jiang C., Magee M.D., Cox R.A. Coadministration of interleukin 12 expression vector with antigen 2 cDNA enhances induction of protective immunity against Coccidioides immitis. Infection and Immunity 1999, 67:5848-5853.
49. Mitsdoerffer M., Lee Y., Jager A., Kim H-J., Korn T., Kolls J.K., et al. Proinflammatory T helper type 17 cells are effective B-cell helpers. PNAS 2010, 107:14292-14297.
50. Wuthrich M., Deepe G., Klein B. Adaptive immunity to fungi. Annual Review of Immunology 2012, 30:115-148.